Pipeline

Cliramitug (formerly ALXN2220, NI006), is a human antibody that exclusively targets with high affinity the disease-associated amyloid conformation but not physiological forms of transthyretin. Cliramitug targets both wild-type ATTR as well as ATTR mutants that are linked to hereditary forms of ATTR cardiomyopathy (ATTR-CM) and ATTR polyneuropathy. Cliramitug induces the clearance of pathological ATTR in preclinical models. Currently, Cliramitug is in Phase 3 clinical development (NCT06183931). The U.S. Food and Drug Administration (FDA) has granted Alexion, AstraZeneca Rare Disease Fast Track designation for the development of ALXN2220 for the treatment of ATTR-CM.

In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop Cliramitug.

AP-101 is a recombinant human antibody designed to selectively deplete toxic, misfolded forms of SOD1 while preserving the protective function of physiological SOD1. By targeting only the pathological conformations, AP-101 aims to disrupt a key driver of ALS progression without lowering total SOD1 levels. Neurimmune and TVM Capital Life Science co-created AL-S Pharma to develop AP-101. AL-S Pharma has executed its innovative clinical plan for AP-101 in collaboration with an international network of ALS experts.

NSC001 is developed by Neurimmune’s collaboration partner NSC Therapeutics GmbH. It is a small, rigid, chemical analog of the cholinergic neurotransmitter acetylcholine in development for the treatment of patients with cholinergic deficits. NSC Therapeutics GmbH received $5 mio funding from the Alzheimer’s Disease Drug Discovery Foundation to support upcoming Phase 2 proof of concept clinical trials.

NG004 is a human antibody blocking the function of Nogo-A, one of the most potent and well-studied nerve growth inhibitors. NG004 is developed by NovaGo Therapeutics for the treatment of spinal cord injury. Novago Therapeutics is a spin-off company from the University of Zurich that entered into a strategic partnership with Neurimmune to discover human antibodies targeting Nogo-A. NovaGo Therapeutics was founded by Prof. Martin Schwab based on the discovery of the existence of “inhibitors of nerve fiber growth” as a cause of the absence of regeneration of injured fiber tracts in the central nervous system.

NI009 is human monoclonal antibody designed to target and deplete light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis.

NI101B3 is a next generation amyloid beta targeting antibody with improved penetration of the blood brain barrier.